Drug intelligence / Profile preview

zopiclone

Development stage
Phase 4
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Zopiclone is a nonbenzodiazepine hypnotic agent from the cyclopyrrolone class, primarily used for the short-term treatment of insomnia in adults. It acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABAA) receptor complex, binding to the benzodiazepine site and enhancing GABAergic neurotransmission. This results in sedative, anxiolytic, muscle relaxant, and anticonvulsant effects similar to those of benzodiazepines. Zopiclone is molecularly distinct from benzodiazepines but shares an almost identical pharmacological profile. It is typically prescribed for 2–4 weeks due to risks of tolerance and dependence with longer use[1][2][3][4][5][6]. Developers: Rhône-Poulenc Manufacturers: Sanofi

Brand names
ImovaneZimovane
Other names
(RS)-zopiclonezopiclonum
02

Targets

GABRR (GABA-A receptor subunit rho)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)GABRA3 (Gamma-aminobutyric acid receptor subunit alpha-3)GABRA5 (Gamma-aminobutyric acid type A receptor subunit alpha-5)

Beyond the preview

Go deeper on zopiclone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on zopiclone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call